VolitionRX Ltd VNRX 深 沪
等待开盘 06-30 09:30:00 美东时间
1.42
+0.140
+10.94%
华盛通- 最 高1.43
- 今 开1.31
- 成交量 30.15万股
- 最 低 1.27
- 昨 收 1.28
- 总市值 1692.71万
- 52周最高 16.00
- 市盈率 静 --
- 换手率 2.53%
- 52周最低 1.17
- 委 比 0.00%
- 总股本 1192.05万
- 历史最高 185.60
- 量 比 1.20
- 振 幅 12.50%
- 历史最低 1.27
- 每 手 1
- 风险率 4.34%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多VolitionRx Partners With Sysmex To Streamline Volition's Nu.Q NETs H3.1 Assay
VolitionRx Limited (NYSE:VNRX) ("Volition"), a multi-national epigenetics company, announces a collaboration with Sysmex (TYO:6869), a leader in global in vitro diagnostics, to optimize Volition's Nu.Q® NETs H3.1 assay on the Sysmex platform.
06-17 20:16
VolitionRx prices public offering to raise USD 4.6 million upfront
VolitionRx prices public offering to raise USD 4.6 million upfront VolitionRx priced a public offering of 2,960,000 common shares with warrants for up to 1,480,000 additional shares. Offering price set at USD 1.55 per share with an accompanying half-warrant; expected gross proceeds about USD 4.6 mil
06-10 18:02
VolitionRx Announces Pricing of $4.6 Million Public Offering
$4.6 million upfront with up to an additional $2.3 million of potential aggregate gross proceeds upon the full exercise of warrants HENDERSON, Nev., June 7, 2026 /PRNewswire/ -- VolitionRx L...
06-08 06:30
U.S. State Dept Announces Nearly $38M In Additional Funding Toward The Department's Ongoing Ebola Response Efforts
https://www.state.gov/releases/office-of-the-spokesperson/2026/06/ebola-response-update-june-5-2026/
06-06 02:24
VolitionRx posts corporate deck outlining Nu.Q diagnostics licensing strategy for cancer, sepsis and veterinary markets
VolitionRx posts corporate deck outlining Nu.Q diagnostics licensing strategy for cancer, sepsis and veterinary markets VolitionRx highlighted an asset-light strategy focused on licensing diagnostics IP, targeting multiple human-health licensing deals in 2026. Veterinary business showed $23 million
05-28 18:59
VolitionRx posts corporate deck outlining Nu.Q licensing strategy across cancer, sepsis and veterinary testing
VolitionRx posts corporate deck outlining Nu.Q licensing strategy across cancer, sepsis and veterinary testing VolitionRx highlighted an asset-light strategy focused on commercial partnerships and out-licensing of its Nu.Q platform across cancer, sepsis, and veterinary testing. Outlined a potential
05-28 18:59
Full Transcript: VolitionRX Q1 2026 Earnings Call
VolitionRX (AMEX:VNRX) held its first-quarter earnings conference call on Frida...
05-15 21:46
VolitionRX Q1 EPS $(0.97) Misses $(0.75) Estimate, Sales $985.076K Beat $426.600K Estimate
VolitionRX (AMEX:VNRX) reported quarterly losses of $(0.97) per share which missed the analyst consensus estimate of $(0.75) by 29.33 percent. This is a 1516.67 percent decrease over losses of $(0.06) per share from the
05-15 04:26
Earnings Scheduled For May 14, 2026
Companies Reporting Before The Bell • Urban One (NASDAQ:UONEK) is expected to r...
05-14 19:11
VolitionRx Submits Clinical Manuscript For Peer Review Over Its Nu.Q Vet Feline Prototype Assay To Trace Lymphoma In Cats
VolitionRx Limited (NYSE:VNRX) ("Volition"), a multi-national epigenetics company, announces submission for peer review a clinical manuscript1 reporting the high accuracy of its Nu.Q® Vet Feline prototype assay in
05-06 20:20
